What is sustained low‑efficiency daily diafiltration (SLEDD‑f) and when is it used in hemodynamically unstable ICU patients with acute kidney injury?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 26, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

What is SLED-F?

SLED-F (Sustained Low-Efficiency Daily Diafiltration) is a hybrid renal replacement therapy that combines prolonged treatment duration (8-12 hours daily) with lower blood and dialysate flow rates than conventional hemodialysis, plus convective clearance through hemofiltration—making it an effective, cost-efficient alternative to continuous renal replacement therapy (CRRT) for hemodynamically unstable ICU patients with acute kidney injury. 1, 2

Technical Specifications

SLED-F operates with the following parameters:

  • Blood flow: 5 mL/kg/min (approximately 200 mL/min) 3, 4
  • Dialysate flow: 200-260 mL/min (much slower than conventional hemodialysis) 3, 4
  • Hemofiltration rate: 35-100 mL/kg/hour 3, 4
  • Treatment duration: 8-10 hours per session, delivered daily or at least on alternate days 4, 5
  • Target delivered dose: Equivalent to 20-25 mL/kg/hour CRRT effluent volume 1, 2

The "diafiltration" component means it combines both diffusive clearance (dialysis) and convective clearance (filtration), providing superior removal of both small and larger solutes compared to dialysis alone 4, 5.

Clinical Applications

SLED-F should be used interchangeably with CRRT for hemodynamically unstable ICU patients with AKI, particularly when CRRT resources are limited. 1 The key indications include:

  • Hemodynamically unstable patients requiring renal replacement therapy 1, 2
  • Critically ill patients with AKI who cannot tolerate conventional intermittent hemodialysis 6, 7
  • Resource-limited settings where CRRT equipment or trained personnel are unavailable 1, 5
  • Situations requiring better hemodynamic stability than intermittent hemodialysis but without 24-hour CRRT infrastructure 8, 5

Advantages Over Other Modalities

SLED-F offers several practical benefits:

  • Hemodynamic stability: Slower fluid and solute shifts prevent intradialytic hypotension (only 5% incidence) 3, 4
  • Cost-effectiveness: Uses standard hemodialysis machines rather than dedicated CRRT equipment, reducing costs significantly 1, 5
  • Resource efficiency: Can be delivered by ICU nursing staff autonomously without continuous nephrology presence 4
  • Adequate clearance: Achieves Kt/V of 1.43 per treatment and equivalent renal urea clearance of 35.7 mL/min, meeting standards for both CRRT and intermittent hemodialysis 4
  • Clinical outcomes: No survival advantage has been demonstrated for CRRT over SLED, with 30-day mortality rates comparable between modalities (54% SLED vs 61% CRRT) 1, 6

When CRRT is Preferred Over SLED-F

Despite its advantages, CRRT remains superior in specific high-risk scenarios:

  • Acute brain injury with elevated intracranial pressure: CRRT's continuous, slower solute removal minimizes intracranial pressure fluctuations 1, 2
  • Severe cerebral edema: Rapid osmotic shifts from intermittent therapies can worsen cerebral edema 1, 2
  • Extreme hemodynamic instability: Patients requiring minute-to-minute fluid adjustments benefit from CRRT's continuous fine-tuning capability 1, 2

Practical Implementation Considerations

Vascular Access

  • Use uncuffed, non-tunneled dialysis catheter in right internal jugular vein as first choice 1, 2
  • Avoid subclavian vein placement due to stenosis risk 1, 2
  • Obtain chest X-ray after jugular or subclavian placement before first session 1

Anticoagulation

  • Regional citrate anticoagulation is first-line when anticoagulation is required 1, 2
  • Heparin can be used safely (76.6% of sessions with no bleeding complications in one series) 3

Monitoring Requirements

  • Check electrolytes every 2-6 hours initially, as SLED-F causes continuous losses of potassium, phosphate, magnesium, and amino acids 1
  • Monitor delivered vs prescribed dose frequently—prescribe 20-25% higher than target to account for interruptions 1
  • Therapeutic drug monitoring essential for dialyzable antibiotics (especially beta-lactams) 1

Nutritional Management

  • Provide 1.5-1.7 g/kg/day protein once hemodynamically stable, accounting for 10-15 g daily amino acid losses 1
  • Target 20-30 kcal/kg/day total energy intake 1
  • Supplement water-soluble vitamins (thiamine, folate, vitamin C) to compensate for dialytic losses 1

Common Pitfalls

The main limitation of SLED-F is staffing availability—delivering 8-hour sessions six days per week requires dialysis personnel coverage that may not be feasible in all centers 1. Additionally, the prescribed dose often exceeds delivered dose due to treatment interruptions, so clinicians must monitor actual effluent volume and adjust prescriptions upward by 20-25% if targets are not met 1.

Related Questions

For an ICU patient with acute kidney injury and limited cardiovascular reserve, what is sustained low‑efficiency dialysis (SLED), how is it performed, and when is it indicated versus continuous renal replacement therapy or intermittent hemodialysis?
What is SLED (Symptomatic Low-Efficiency Daily dialysis)?
What is the preferred renal replacement therapy, Continuous Kidney Replacement Therapy (CKRT) or Sustained Low-Efficiency Dialysis (SLED), for patients with severe impaired renal function?
What are the differences between Hemodialysis (HD), Sustained Low-Efficiency Dialysis (SLED), and Continuous Renal Replacement Therapy (CRRT) for a patient with impaired renal function?
What are the differences between Sustained Low-Efficiency Dialysis (SLED) and normal Hemodialysis (HD) for critically ill patients with Impaired renal function?
In a kidney transplant recipient with iron‑deficiency anemia (hemoglobin ~9.5 g/dL, serum iron 18 µg/dL, transferrin saturation ~6 %, total iron‑binding capacity 304 µg/dL), what is the recommended first‑line therapy and when should treatment be escalated to intravenous iron?
What are the indications, dosing regimens, adverse effects, and alternative therapies for Sandostatin (octreotide)?
What is the recommended initial management for bursitis?
In a child with a total cholesterol of 51 mg/dL and low high‑density lipoprotein, what is the significance and how should it be evaluated and managed?
How should I taper a selective serotonin reuptake inhibitor (SSRI) safely?
What is the recommended management of hypomagnesemia, including oral and intravenous dosing, monitoring, and treatment of underlying causes, based on severity and renal function?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.